breast cancer

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.

[Science Advances] Scientists identified a lectin, SLBR-N, which bound to O-linked α2,3 sialic acids, that was able to enrich for CSCs in vitro and in vivo. This O-glycan was expressed on CD44 and promoted its interaction with hyaluronic acid, facilitating CD44 signaling and CSC properties.

[Cancer] Researchers review the role of tumor-infiltrating Tregs in tumor progression and metabolic reprogramming of the tumor microenvironment.

[Cancer Immunology Research] Investigators combined intratumoral STimulator of INterferon Genes (STING) agonist therapy with systemically injected extended half-life IL2 and anti–PD-1 checkpoint blockade to drive innate and adaptive antitumor immunity in models of triple-negative breast cancer.

[Zai Lab Limited] Zai Lab Limited announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for margetuximab, an investigational, Fc-engineered monoclonal antibody that targets HER2.

[Cell Death & Differentiation] Researchers uncovered a previously unrecognized mechanistic role for MORC family CW-type zinc finger 2 (MORC2) O-GlcNAcylation in breast cancer progression and provided evidence for targeting MORC2-dependent breast cancer through blocking its O-GlcNAcylation.